STUDIES ON EFFECT OF FORMULATION AND PROCESSING PARAMETERS ON STABILITY OF KETOROLAC TROMETHAMINE ORALLY DISSOLVING FILMS
Objective: The objective of the proposed work was to study the effect of various formulation and process parameters of solvent casting method on the physical and chemical stability of Ketorolac Tromethamine (KT) in the orally dissolving film dosage form.
Methods: KT-excipient interaction study was carried out both in solid state and by processing samples through the solvent casting technique. The samples were evaluated using IR spectroscopy (IR) and X-ray diffractometry (XRD). Solvent casting method was used to prepare KT films using different film-forming polymers, and solvents. The drying temperature and pH of the dispersion were also varied to study the effect of these parameters on the stability of KT. All the formulations were analysed chemically initially and after one month of storage at 40 °C/75% RH.
Results: During KT-excipient interaction study in solid state KT was found to be stable. No significant changes were observed in its impurity profile. Interaction between different polymers and KT was observed after the solvent casting process as revealed by IR and XRD analysis. The interaction was further confirmed in the film formulations upon chemical analysis. The polymers showing interaction with KT in XRD and IR were making it unstable chemically and were responsible for its chemical degradation as revealed by chemical analysis. It was also revealed that KT is most stable when processed using water as the solvent. KT was found to be stable when processed at a higher temperature and at acidic pH during film formation. It was found that chemical stability is more when Polyethylene oxide (PEO) and water under acidic pH are used and films are dried at a higher temperature.
Conclusion: Both formulation parameters and processing conditions of the solvent casting technique affects the stability of drugs and hence should be studied as part of pre-formulation studies while developing orally dissolving films of drugs.
2. Kalariya PD, Raju B, Borkar RM, Namdev D, Gananadhamu S, Nandekar PP, et al. Characterization of forced degradation products of ketorolac tromethamine using LC/ESI/Q/TOF/MS/MS and in silico toxicity prediction. J Mass Spectrom 2014;49:380-91.
3. Salaris M, Nieddu M, Rubattu N, Testa C, Luongo E, Rimoli MG, et al. Acid and base degraded product of ketorolac. J Pharm Biomed Anal 2010;52:320-2.
4. Devarajan PV, Gore SP, Chavan SV. HPTLC determination of ketorolac tromethamine. J Pharm Biomed Anal 2000;22:679-83.
5. Leo G, Chiang H, Becker A. Kinetics and mechanisms of the autoxidation of ketorolac tromethamine in aqueous solution. Int J Pharm 1988;41:95-104.
6. Leo G, Chiang H, Johnson D. Light degradation of ketorolac tromethamine. Int J Pharm 1988;41:105-13.
7. Toradol Oral. Available from: https://www.accessdata. fda.gov/drugsatfda_docs/label/2013/019645s019lbl. pdf. [Last accessed on 15 Dec 2018]
8. Ketorolac Tromethamine Injection. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/204216Orig1s000ltr.pdf. [Last accessed on 15 Dec 2018]
9. Sprix Nasal Spray. Available from: https:// www.accessdata.fda.gov/drugsatfda_docs/label/2010/022382s000lbl.pdf. [Last accessed on 15 Dec 2018]
10. Acular Ophthalmic solution. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/19700S023,024lbl.pdf. [Last accessed on 15 Dec 2018]
11. Kumar De P, Mallick S, Mukherjee B, Sengupta S, Pattnaik S, Chakraborty S. Optimization of in vitro permeation pattern of ketorolac tromethamine transdermal patches. Iranian J Pharm Res 2011;10:193-201.
12. Xu ZP, Gu Z, Cheng X, Rasoul F, Whittaker AK, Max Lu GQ. Controlled release of ketorolac through nanocomposite films of hydrogel and LDH nanoparticles. J Nanopart Res 2011;13:1253-64.
13. Rudra VS, Birla RV, Katakam M, Inventors. Sublingual film of ketorolac. Patent Application No. WO2016151461A1; 2016.
14. El-Nabarawi MA, Makky AM, El-Setouhy DA, ABD Elmonem RA, Jasti BA. Development and characterization of ketorolac tromethamine (KT) orobuccal films. Int J Pharm Pharm Sci 2012;4:186-93.
15. Katdare A, Chaubal M. Excipient development for pharmaceutical, biotechnology, and drug delivery systems. Taylor and Francis Group LLC; 2006. p. 101-4.
16. Hoffmann EM, Breitenbach A, Breitkreutz J. Advances in orodispersible films for drug delivery. Expert Opin Drug Delivery 2011;8:299-316.
17. Daud AS, Sapkal NP, Bonde MN. Development of Zingiber officinale in oral dissolving films: Effect of polymers on in vitro, in vivo parameters and clinical efficacy. Asian J Pharm 2011;5:183-9.
18. Daud AS, Sapkal NP, Bonde MN, Gaikwad N. To study the effect of solvent, viscosity, and temperature on the mouth-dissolving film of Withania somnifera linn. Asian J Pharm 2012;6:212-7.
19. Ivanisevic I. Physical stability studies of miscible amorphous solid dispersions. J Pharm Sci 2010;99:4005-12.
20. Meng F, Trivino A, Prasad D, Chauhan H. Investigation and correlation of drug-polymer miscibility and molecular interactions by various approaches for the preparation of amorphous solid dispersions. Eur J Pharm Sci 2015;71:12–24.
21. Nagarsenker MS, Meshram RN, Ramprakash G. Solid dispersion of hydroxypropyl-beta-cyclodextrin and ketorolac: enhancement of in vitro dissolution rates, improvement in anti-inflammatory activity and reduction in ulcerogenicity in rats. J Pharm Pharmacol 2000;52:949-56.
22. Basu SK, Kavitha K, Rupeshkumar M. Evaluation of ketorolac tromethamine microspheres by chitosan/gelatin B complex coacervation. Sci Pharm 2010;78:79-92.
23. Brandl M, Magil A, Rudraraju V, Gordon MS. Approaches for improving the stability of ketorolac in powder blends. J Pharm Sci 1995;84:1151-3.
This work is licensed under a Creative Commons Attribution 4.0 International License.